-
公开(公告)号：US20200149069A1
公开(公告)日：2020-05-14
申请号：US16751470
申请日：2020-01-24
Applicant: The Government of the United States of America as Represented by the Secretary of the Department of , GlaxoSmithKline Biologicals SA
Inventor： Nancy J. Sullivan , Gary J. Nabel , Clement Asiedu , Cheng Cheng , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Stefano Colloca
IPC: C12N15/86 , C12N7/00 , C07K14/005 , A61K39/12
Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
-
公开(公告)号：US10576143B2
公开(公告)日：2020-03-03
申请号：US15461978
申请日：2017-03-17
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor： Stefano Colloca , Riccardo Cortese , Antonella Folgori , Alfredo Nicosia
Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
-
Patent Agency Ranking
公开(公告)号：US10544192B2
公开(公告)日：2020-01-28
申请号：US15623723
申请日：2017-06-15
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefano Colloca , Alfredo Nicosia , Riccardo Cortese, Sr. , Virginia Ammendola , Maria Ambrosio
IPC: C07K14/005 , A61K39/12 , A61K39/235 , C12N7/00 , C12N15/86 , A61K39/00 , A61K48/00
Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.
-
14.发明申请公开(公告)号：US20180057540A1
公开(公告)日：2018-03-01
申请号：US15623723
申请日：2017-06-15
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefano Colloca , Alfredo Nicosia , Riccardo Cortese, Sr. , Virginia Ammendola , Maria Ambrosio
IPC: C07K14/005 , C12N15/86 , A61K39/12 , A61K39/235 , C12N7/00 , A61K39/00 , A61K48/00
CPC classification number: C07K14/005 , A61K39/0011 , A61K39/12 , A61K39/235 , A61K48/00 , A61K2039/525 , A61K2039/5256 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/10321 , C12N2710/10322 , C12N2710/10334 , C12N2710/10343 , C12N2710/16634 , C12N2740/16134 , C12N2770/24234
Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.
-
15.发明授权公开(公告)号：US11859199B2
公开(公告)日：2024-01-02
申请号：US16756380
申请日：2018-10-16
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefano Colloca
IPC: C12N15/00 , C12N15/86 , A61K39/235
CPC classification number: C12N15/86 , A61K39/235 , C12N2710/10343 , C12N2710/16121 , C12N2830/48
Abstract: An adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein each transgene encodes an RSV antigenic protein or a fragment thereof.
-
公开(公告)号：US11278614B2
公开(公告)日：2022-03-22
申请号：US16782268
申请日：2020-02-05
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefano Colloca , Riccardo Cortese , Antonella Folgori , Alfredo Nicosia
IPC: C12N15/863 , A61K39/00 , C07K14/74 , C07K14/005 , A61K39/29 , C12N7/00 , C12N15/86
Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
-
公开(公告)号：US11268108B2
公开(公告)日：2022-03-08
申请号：US16756376
申请日：2018-10-16
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia Ammendola , Stefano Colloca , Alessandra Vitelli
Abstract: Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.
-
-
-
-
-
-
Search Results
17
records
(took 0.018 seconds)
